Massivemarkets

LGVN

Longeveron Inc. Common Stock

Nasdaq · usd

$2.48+0.47 (+23.38%)
As of 11:35:48 AM EST on Nov 10, 2026 · 15-minute delayed

Longeveron Inc. Common Stock (LGVN) trades at $2.48 (+23.38%) as of 11:35:48 AM EST on Nov 10, 2026, +0.82% over the past month. Market cap is $6.41M, with 1.0 days to cover in short interest.

Stock performance

How Longeveron Inc. Common Stock (LGVN) stock has performed from one day to one year, with its 52-week range.

+17.62%
+$0.37 over 1D
$2.05$2.19$2.33$2.475:25 AM9:55 AM10:20 AM11:00 AM11:25 AM$2.47
1D
+22.89%
1W
+38.76%
1M
+0.82%
YTD
-51.19%
1Y
-65.56%
52-wk range
$1.31 – $12.30

Key statistics

Today's trading snapshot for LGVN: day range, open, previous close, volume and market cap.

Day range
$1.98 – $2.54
Open
$2.08
Prev close
$2.01
Volume
120.87K
Market cap
$6.41M
Shares out
3.04M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Longeveron Inc. Common Stock: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
5.40
P/B
0.62
P/FCF
—
ROE
-225.7%
ROA
-151.6%
Debt/Equity
0.00
Div yield
0.00%

As of Nov 9, 2026

8-K filings

Material corporate events Longeveron Inc. Common Stock has disclosed to the SEC on Form 8-K.

  • Director departureNov 5, 2026

    On November 1, 2026, Ms. Ursula Ungaro provided Longeveron Inc. (the "Company") with notice of her immediate resignation from the Company's Board of Directors and its Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Special Committee. Ms. Ungaro indicated that her decision to resign was due to personal health issues and not the result of any disagreement with the Company on any matter related to the Company's operations, policies, or practices.

  • Longeveron Inc. issued a press release announcing updated results from ELPIS II, its Phase 2b clinical trial evaluating laromestrocel in 40 infants with hypoplastic left heart syndrome. The trial did not meet its primary efficacy endpoint, but the secondary endpoint analysis showed eight major adverse cardiac events in the standard-of-care arm versus one in the laromestrocel arm (P=0.043).

  • On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026.

  • On September 16, 2026, Longeveron Inc. issued a press release announcing topline results from ELPIS II, its Phase 2b clinical trial evaluating the Company's investigational stem cell therapy, laromestrocel, as an adjunct to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome ("HLHS"). The ELPIS II trial did not meet the primary efficacy endpoint of change from baseline in right ventricular ejection fraction ("RVEF") at Month 12.

  • On September 11, 2026, the Company received written notification from Nasdaq indicating that the Company's Common Stock had a closing price of $1.00 per share or greater for the last 10 consecutive business days, from August 27, 2026 until September 10, 2026, and that, as a result, the Company has regained compliance with the Minimum Bid Price Requirement and the matter is now closed.

Dividend history and stock splits

Longeveron Inc. Common Stock's recent dividend payments and stock splits.

Dividends

No recent dividends.

Splits

  • 1-for-10Aug 27, 2026
  • 1-for-10Mar 27, 2024

LGVN short interest

How heavily LGVN is shorted: shares short, days to cover and average daily volume.

Days to cover
1.0
Short interest
73.18K
Avg volume
73.33K

As of · reported to FINRA twice monthly.

LGVN news

The latest news and headlines about Longeveron Inc. Common Stock (LGVN).

Frequently asked questions

What is the Longeveron Inc. Common Stock (LGVN) stock price today?

Longeveron Inc. Common Stock (LGVN) is trading at $2.48 (+23.38% on the day) as of 11:35:48 AM EST on Nov 10, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Longeveron Inc. Common Stock?

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel.

What is the short interest in LGVN?

As of Oct 15, 2026, LGVN has 73.18K shares short and 1.0 days to cover.

What exchange is LGVN listed on?

Longeveron Inc. Common Stock (LGVN) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of LGVN with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a LGVN analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.